MA27671A1 - Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement - Google Patents
Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquementInfo
- Publication number
- MA27671A1 MA27671A1 MA28526A MA28526A MA27671A1 MA 27671 A1 MA27671 A1 MA 27671A1 MA 28526 A MA28526 A MA 28526A MA 28526 A MA28526 A MA 28526A MA 27671 A1 MA27671 A1 MA 27671A1
- Authority
- MA
- Morocco
- Prior art keywords
- rapamycin
- treatment
- combination
- pharmaceutical compositions
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur des compositions pharmaceutiques comprenant en combinaison la rapamycine ou un dérivé de rapamycine et un composé de formule (I), ces compositions pouvant être utiles dans le traitement de maladies inflammatoires et de maladies induites immunologiquement, telles que les maladies auto-immunes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0306070A GB0306070D0 (en) | 2003-03-17 | 2003-03-17 | Organic compounds |
GB0306868A GB0306868D0 (en) | 2003-03-25 | 2003-03-25 | Organic compounds |
GB0319226A GB0319226D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27671A1 true MA27671A1 (fr) | 2005-12-01 |
Family
ID=33032928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28526A MA27671A1 (fr) | 2003-03-17 | 2005-09-30 | Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement |
Country Status (26)
Country | Link |
---|---|
US (1) | US20060154952A1 (fr) |
EP (1) | EP1608368B8 (fr) |
JP (1) | JP2006515017A (fr) |
KR (1) | KR100855140B1 (fr) |
AR (1) | AR043504A1 (fr) |
AT (1) | ATE409479T1 (fr) |
AU (1) | AU2004222563B2 (fr) |
BR (1) | BRPI0408423A (fr) |
CA (2) | CA2633287A1 (fr) |
CL (1) | CL2004000535A1 (fr) |
DE (1) | DE602004016830D1 (fr) |
EC (1) | ECSP056006A (fr) |
ES (1) | ES2315648T3 (fr) |
HK (1) | HK1086743A1 (fr) |
HR (1) | HRP20050800A2 (fr) |
IS (1) | IS8028A (fr) |
MA (1) | MA27671A1 (fr) |
MX (1) | MXPA05009934A (fr) |
MY (1) | MY137868A (fr) |
NO (1) | NO20054778L (fr) |
PE (1) | PE20050313A1 (fr) |
PL (1) | PL1608368T3 (fr) |
PT (1) | PT1608368E (fr) |
TN (1) | TNSN05197A1 (fr) |
TW (2) | TW200503703A (fr) |
WO (1) | WO2004082681A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050461A1 (fr) * | 2004-10-28 | 2006-05-11 | Wyeth | Utilisation d'un inhibiteur mtor dans le traitement de leiomyomes uterins |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
EP2278966B1 (fr) * | 2008-03-21 | 2019-10-09 | The University of Chicago | Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor |
MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
RU2449806C1 (ru) * | 2010-11-30 | 2012-05-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ лечения красного плоского лишая слизистой оболочки полости рта |
EP2948134B1 (fr) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions pour une administration transdermique d'inhibiteurs de mtor |
WO2015054280A1 (fr) | 2013-10-08 | 2015-04-16 | Lam Therapeutics, Inc. | Rapamycine pour le traitement de la lymphangioléiomyomatose |
HRP20230863T1 (hr) * | 2014-04-04 | 2023-11-10 | AI Therapeutics, Inc. | Inhalacijska formulacija rapamicina, namijenjena liječenju stanja povezanih sa starenjem |
MX2017004440A (es) | 2014-10-07 | 2017-11-01 | Lam Therapeutics Inc | Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar. |
US10851144B2 (en) | 2015-04-10 | 2020-12-01 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
EP3565520A4 (fr) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation |
JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物および使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69021833T2 (de) * | 1989-11-09 | 1996-03-21 | Sandoz Ag | Heteroatome enthaltende tricyclische Verbindungen. |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
NZ333657A (en) * | 1996-07-30 | 2000-05-26 | Novartis Ag | A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin |
GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
BR0209474A (pt) * | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
CN1615137A (zh) * | 2002-01-10 | 2005-05-11 | 诺瓦提斯公司 | 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送系统 |
NZ536331A (en) * | 2002-05-09 | 2007-08-31 | Hemoteq Ag | Compounds and method for coating surfaces of medical devices such as stents in a haemocompatible manner |
-
2004
- 2004-03-08 AR ARP040100730A patent/AR043504A1/es not_active Application Discontinuation
- 2004-03-15 TW TW093106848A patent/TW200503703A/zh unknown
- 2004-03-15 TW TW097116133A patent/TW200835484A/zh unknown
- 2004-03-15 PE PE2004000273A patent/PE20050313A1/es not_active Application Discontinuation
- 2004-03-16 JP JP2005518678A patent/JP2006515017A/ja active Pending
- 2004-03-16 EP EP04720871A patent/EP1608368B8/fr not_active Expired - Lifetime
- 2004-03-16 CA CA002633287A patent/CA2633287A1/fr not_active Abandoned
- 2004-03-16 KR KR1020057017469A patent/KR100855140B1/ko not_active IP Right Cessation
- 2004-03-16 CA CA002517671A patent/CA2517671A1/fr not_active Abandoned
- 2004-03-16 PL PL04720871T patent/PL1608368T3/pl unknown
- 2004-03-16 BR BRPI0408423-3A patent/BRPI0408423A/pt not_active IP Right Cessation
- 2004-03-16 MY MYPI20040914A patent/MY137868A/en unknown
- 2004-03-16 AU AU2004222563A patent/AU2004222563B2/en not_active Ceased
- 2004-03-16 MX MXPA05009934A patent/MXPA05009934A/es not_active Application Discontinuation
- 2004-03-16 DE DE602004016830T patent/DE602004016830D1/de not_active Expired - Fee Related
- 2004-03-16 US US10/547,185 patent/US20060154952A1/en not_active Abandoned
- 2004-03-16 CL CL200400535A patent/CL2004000535A1/es unknown
- 2004-03-16 ES ES04720871T patent/ES2315648T3/es not_active Expired - Lifetime
- 2004-03-16 WO PCT/EP2004/002714 patent/WO2004082681A1/fr active IP Right Grant
- 2004-03-16 AT AT04720871T patent/ATE409479T1/de not_active IP Right Cessation
- 2004-03-16 PT PT04720871T patent/PT1608368E/pt unknown
-
2005
- 2005-08-17 TN TNP2005000197A patent/TNSN05197A1/en unknown
- 2005-09-08 EC EC2005006006A patent/ECSP056006A/es unknown
- 2005-09-12 HR HR20050800A patent/HRP20050800A2/xx not_active Application Discontinuation
- 2005-09-15 IS IS8028A patent/IS8028A/is unknown
- 2005-09-30 MA MA28526A patent/MA27671A1/fr unknown
- 2005-10-17 NO NO20054778A patent/NO20054778L/no not_active Application Discontinuation
-
2006
- 2006-06-13 HK HK06106761.8A patent/HK1086743A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE602004016830D1 (de) | 2008-11-13 |
WO2004082681A1 (fr) | 2004-09-30 |
IS8028A (is) | 2005-09-15 |
CA2517671A1 (fr) | 2004-09-30 |
TNSN05197A1 (en) | 2007-06-11 |
AR043504A1 (es) | 2005-08-03 |
WO2004082681B1 (fr) | 2004-11-25 |
AU2004222563A1 (en) | 2004-09-30 |
ES2315648T3 (es) | 2009-04-01 |
PL1608368T3 (pl) | 2009-03-31 |
EP1608368B1 (fr) | 2008-10-01 |
PT1608368E (pt) | 2009-01-27 |
BRPI0408423A (pt) | 2006-03-21 |
HRP20050800A2 (en) | 2006-11-30 |
PE20050313A1 (es) | 2005-06-14 |
EP1608368B8 (fr) | 2009-06-10 |
EP1608368A1 (fr) | 2005-12-28 |
NO20054778L (no) | 2005-12-19 |
CA2633287A1 (fr) | 2004-09-30 |
US20060154952A1 (en) | 2006-07-13 |
JP2006515017A (ja) | 2006-05-18 |
TW200503703A (en) | 2005-02-01 |
ATE409479T1 (de) | 2008-10-15 |
MY137868A (en) | 2009-03-31 |
TW200835484A (en) | 2008-09-01 |
AU2004222563B2 (en) | 2006-11-02 |
CL2004000535A1 (es) | 2005-01-14 |
MXPA05009934A (es) | 2006-03-21 |
KR100855140B1 (ko) | 2008-08-28 |
HK1086743A1 (en) | 2006-09-29 |
NO20054778D0 (no) | 2005-10-17 |
ECSP056006A (es) | 2006-01-27 |
KR20050110023A (ko) | 2005-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27671A1 (fr) | Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
ATE371645T1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
MXPA05009595A (es) | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. | |
DE602004013563D1 (de) | Rantagonisten | |
JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
MA32231B1 (fr) | Composés organiques | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA28269A1 (fr) | Arylpyrazoles substitués servant d'agents parasiticides | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
MA30207B1 (fr) | Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide | |
MA29213B1 (fr) | Quinolones a substitution macrolones - amino | |
MA27661A1 (fr) | Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant | |
DE60206198D1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
MA32931B1 (fr) | Compositions antimicrobiennes | |
TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents |